Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome

Hypertension and Obesity (E Reisin, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hypertension and Obesity

Abstract

Purpose of Review

This review will summarize recent developments in the research on the mineralocorticoid receptor and its impact on obstructive sleep apnea and metabolic syndrome.

Recent Findings

Aldosterone excess plays an important role in the association between resistant hypertension and obstructive sleep apnea. The prevalence of obesity is increasing rapidly worldwide and is especially common among patients with obstructive sleep apnea, resistant hypertension, and metabolic syndrome, suggesting probable mechanistic links between these three conditions. Mineralocorticoid receptor expression is increased in obese individuals, which may contribute to the common association between obesity and hyperaldosteronism. Mineralocorticoid receptor blockers reduce the severity of obstructive sleep apnea among resistant hypertension patients.

Summary

A large body of literature demonstrates a strong association between obesity, hyperaldosteronism, resistant hypertension, and sleep apnea, including specific benefit of treatment with mineralocorticoid receptor blockers for these separate disorders.

Keywords

Obstructive sleep apnea Resistant hypertension Obesity Aldosterone Metabolic syndrome Mineralocorticoid receptor antagonists 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • of importance •• of major importance

  1. 1.
    •• Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. Journal of Human Hypertension. 2012;26(5):281–7. This reference is important since the review gives a detailed overview of existing literature and the shortcomings in the association between aldosterone, OSA and RHTN.  https://doi.org/10.1038/jhh.2011.47.CrossRefPubMedGoogle Scholar
  2. 2.
    Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. In: Seminars in nephrology 2007 Sep 30 (Vol. 27, no. 5, pp. 529-537). WB Saunders.Google Scholar
  3. 3.
    Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep. 2010;12(4):252–7.  https://doi.org/10.1007/s11906-010-0126-2.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gomez-Sanchez CE. What is the role of the adipocyte mineralocorticoid receptor in the metabolic syndrome?.Google Scholar
  5. 5.
    Feliciano Pereira P, Priore SE, Bressan J. Aldosterone: a cardiometabolic risk hormone? Nutricion Hospitalaria. 2014;30(6)Google Scholar
  6. 6.
    Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65(2):257–63.  https://doi.org/10.1161/HYPERTENSIONAHA.114.04488.CrossRefPubMedGoogle Scholar
  7. 7.
    Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24(8):532–7.  https://doi.org/10.1038/jhh.2009.96.CrossRefPubMedGoogle Scholar
  8. 8.
    Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–8.  https://doi.org/10.1111/j.1467-789X.2009.00623.x.CrossRefPubMedGoogle Scholar
  9. 9.
    Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12):2271–7.  https://doi.org/10.1097/00004872-200112000-00022.CrossRefPubMedGoogle Scholar
  10. 10.
    • Prejbisz A, Florczak E, Klisiewicz A, Dobrowolski P, Janaszek-Sitkowska H, Bieleń P, et al. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension. Endokrynologia Polska. 2013;64(5):363–7. The study showed that PA was associated with more pronounced LVH, while OSA was associated with concentric remodeling among OSA patients with RHTN and PA. CrossRefPubMedGoogle Scholar
  11. 11.
    Ke X, Guo W, Peng H, Hu C, Zhang H, Peng C, et al. Association of aldosterone excess and apnea-hypopnea index in patients with resistant hypertension. Sci Rep. 2017;7:45241.  https://doi.org/10.1038/srep45241.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    •• Barceló A, Piérola J, Esquinas C, de la Peña M, Arqué M, Alonso-Fernández A, et al. Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. PloS One. 2014;9(1):e84362. This study showed that aldosterone levels are associated with MS, suggesting that aldosterone excess might predispose or aggravate the metabolic and cardiovascular complications in OSA patients. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    •• Krasinska B, Miazga A, Cofta S, Szczepaniak-Chichel L, Trafas T, Krasinski Z, et al. Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension. Pol Arch Med Wewn. 2016;126(5):330–9. This reference is important as it provides a new insight for the treatment of OSA with MRAs. It showed that eplerenone therapy significantly reduced the severity of OSA and arterial stiffness in patients with RHTN and OSA PubMedGoogle Scholar
  14. 14.
    Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Leiby BE, Vela-Bueno A, et al. Association of hypertension and sleep-disordered breathing. Arch Intern Med. 2000 Aug 14;160(15):2289–95.  https://doi.org/10.1001/archinte.160.15.2289.CrossRefPubMedGoogle Scholar
  15. 15.
    Walia HK, Li H, Rueschman M, Bhatt DL, Patel SR, Quan SF, et al. Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. J Clin Sleep Med. 2014;10(8):835–43.  https://doi.org/10.5664/jcsm.3946.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342(19):1378–84.  https://doi.org/10.1056/NEJM200005113421901.CrossRefPubMedGoogle Scholar
  17. 17.
    Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med. 1997;157(15):1746–52.  https://doi.org/10.1001/archinte.1997.00440360178019.CrossRefPubMedGoogle Scholar
  18. 18.
    Marin JM, Agusti A, Villar I, Forner M, Nieto D, Carrizo SJ, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA. 2012;307(20):2169–76.  https://doi.org/10.1001/jama.2012.3418.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    O'Connor GT, Caffo B, Newman AB, Quan SF, Rapoport DM, Redline S, et al. Prospective study of sleep-disordered breathing and hypertension: the Sleep Heart Health Study. Am J Respir Crit Care Med. 2009;179(12):1159–64.  https://doi.org/10.1164/rccm.200712-1809OC.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cano-Pumarega I, Durán-Cantolla J, Aizpuru F, Miranda-Serrano E, Rubio R, Martínez-Null C, et al. Obstructive sleep apnea and systemic hypertension: longitudinal study in the general population: the Vitoria Sleep Cohort. Am J Respir Crit Care Med. 2011;184(11):1299–304.  https://doi.org/10.1164/rccm.201101-0130OC.CrossRefPubMedGoogle Scholar
  21. 21.
    Pankow W, Nabe B, Lies A, Becker H, Köhler U, Kohl FV, et al. Influence of sleep apnea on 24-hour blood pressure. Chest. 1997;112(5):1253–8.  https://doi.org/10.1378/chest.112.5.1253.CrossRefPubMedGoogle Scholar
  22. 22.
    Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219–29.  https://doi.org/10.1016/S0140-6736(07)61538-4.CrossRefPubMedGoogle Scholar
  23. 23.
    Muxfeldt ES, Margallo VS, Guimarães GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens. 2014;27(8):1069–78.  https://doi.org/10.1093/ajh/hpu023.CrossRefPubMedGoogle Scholar
  24. 24.
    Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. CHEST J. 2007;131(2):453–9.  https://doi.org/10.1378/chest.06-1442.CrossRefGoogle Scholar
  25. 25.
    • Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine. 2010;6(4):363. The study confirmed a markedly high prevalence of OSA among RHTN patients. The study also showed that severity of OSA was greater in those patients with hyperaldosteronism and related to the degree of aldosterone excess Google Scholar
  26. 26.
    Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. CHEST J. 2007;132(2):440–6.CrossRefGoogle Scholar
  27. 27.
    Kasai T, Bradley TD, Friedman O, Logan AG. Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension. J Hypertens. 2014 Mar 1;32(3):673–80.  https://doi.org/10.1097/HJH.0000000000000047.CrossRefPubMedGoogle Scholar
  28. 28.
    Møller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens. 2003 Apr 1;16(4):274–80.  https://doi.org/10.1016/S0895-7061(02)03267-3.CrossRefPubMedGoogle Scholar
  29. 29.
    Svatikova A, Olson LJ, Wolk R, Phillips BG, Adachi T, Schwartz GL, et al. Obstructive sleep apnea and aldosterone. Sleep. 2009 Dec 1;32(12):1589–92.  https://doi.org/10.1093/sleep/32.12.1589.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Rocchini AP, Katch VL, Grekin R, Moorehead C, Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol. 1986 May 3;57(8):613–8.  https://doi.org/10.1016/0002-9149(86)90845-3.CrossRefPubMedGoogle Scholar
  31. 31.
    Cat AN, Friederich-Persson M, White A, Touyz RM. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 2016;57(1):F7–21.CrossRefGoogle Scholar
  32. 32.
    • Urbanet R, Cat AN, Feraco A, Venteclef N, El Mogrhabi S, Sierra-Ramos C, De La Rosa DA, Adler GK, Quilliot D, Rossignol P, Fallo F. Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase. Hypertension. 2015 . This study is important since it showed overactivation of MR in adipocytes participates in the development of MS, supporting the rationale for further clinical studies to evaluate the potential benefit of MRAs in patients with adipose tissue overexpressing MR, such as in obese individuals or those with MS. Google Scholar
  33. 33.
    Luther JM. Aldosterone in vascular and metabolic dysfunction. Curr Opin Nephrol Hypertens. 2016 Jan;25(1):16–21.  https://doi.org/10.1097/MNH.0000000000000189.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Vecchiola A, Lagos CF, Carvajal CA, Baudrand R, Fardella CE. Aldosterone production and signaling dysregulation in obesity. Curr Hypertens Rep. 2016;18(3):20.  https://doi.org/10.1007/s11906-016-0626-9.CrossRefPubMedGoogle Scholar
  35. 35.
    Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009 Jun 2;150(11):776–83.  https://doi.org/10.7326/0003-4819-150-11-200906020-00005.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010 Apr 30;52(5):401–9.  https://doi.org/10.1016/j.pcad.2009.12.004.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007 Oct 12;370(9594):1219–29.  https://doi.org/10.1016/S0140-6736(07)61538-4.CrossRefPubMedGoogle Scholar
  38. 38.
    Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981 Apr 16;304(16):930–3.CrossRefPubMedGoogle Scholar
  39. 39.
    Levy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J. 2009;34(1):243–60.CrossRefPubMedGoogle Scholar
  40. 40.
    Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006 Feb 1;91(2):454–9.  https://doi.org/10.1210/jc.2005-1733.CrossRefPubMedGoogle Scholar
  41. 41.
    Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007 Mar 1;49(3):704–11.  https://doi.org/10.1161/01.HYP.0000253258.36141.c7.CrossRefPubMedGoogle Scholar
  42. 42.
    Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006 Aug 1;48(2):239–45.  https://doi.org/10.1161/01.HYP.0000231338.41548.fc.CrossRefPubMedGoogle Scholar
  43. 43.
    Hannemann A, Meisinger C, Bidlingmaier M, Döring A, Thorand B, Heier M, et al. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol. 2011;164(5):751–8.  https://doi.org/10.1530/EJE-10-1074.CrossRefPubMedGoogle Scholar
  44. 44.
    Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors. Circulation. 2007;116(9):984–92.  https://doi.org/10.1161/CIRCULATIONAHA.107.708537.CrossRefPubMedGoogle Scholar
  45. 45.
    •• Garg R, Adler GK. Aldosterone and the mineralocorticoid receptor: risk factors for cardiometabolic disorders. Curr Hypertens Rep. 2015;17(7):1–8. This reference summarizes the relationship between mineralocorticoid receptor and metabolic syndrome, and the role of MRAs in reducing the cardiovascular outcomes in patients with diabetes and obesity. CrossRefGoogle Scholar
  46. 46.
    Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Dessì-Fulgheri P, Sarzani R, Burnett JC. Circulating aldosterone and natriuretic peptides in the general community. Hypertension 2014 :HYPERTENSIONAHA-114.Google Scholar
  47. 47.
    Späth M, Korovkin S, Antke C, Anlauf M, Willenberg HS. Aldosterone-and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. Eur J Endocrinol. 2011 Apr 1;164(4):447–55.  https://doi.org/10.1530/EJE-10-1070.CrossRefPubMedGoogle Scholar
  48. 48.
    Fujimoto K, Honjo S, Tatsuoka H, Hamamoto Y, Kawasaki Y, Matsuoka A, et al. Primary aldosteronism associated with subclinical Cushing syndrome. J Endocrinol Investig. 2013;36(8):564–7.Google Scholar
  49. 49.
    • Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, et al. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens. 2016;38(5):464–8. The study showed that spironolactone reduced the severity of OSA in RHTN patients with moderate to severe OSA in addition to reducing blood pressure. CrossRefPubMedGoogle Scholar
  50. 50.
    Garg R, Kneen L, Williams GH, Adler GK. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab. 2014 Mar 1;16(3):268–72.  https://doi.org/10.1111/dom.12224.CrossRefPubMedGoogle Scholar
  51. 51.
    Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91(9):3457–63.  https://doi.org/10.1210/jc.2006-0736.CrossRefPubMedGoogle Scholar
  52. 52.
    Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101(6):594–7.  https://doi.org/10.1161/01.CIR.101.6.594.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Vascular Biology and Hypertension ProgramUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations